Ligand Pharmaceuticals Incorporated (LGND)
Jul 2, 2025 - LGND was delisted (reason: merged into PTHS)
113.30
+0.74 (0.66%)
Inactive · Last trade price on Jul 2, 2025

Company Description

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.

It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.

The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes.

In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis.

Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder.

The company was incorporated in 1987 and is based in Jupiter, Florida.

Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals logo
CountryUnited States
Founded1987
IPO DateNov 18, 1992
IndustryBiotechnology
SectorHealthcare
Employees68
CEOTodd Davis

Contact Details

Address:
555 Heritage Drive, Suite 200
Jupiter, Florida 33458
United States
Phone858 550 7500
Websiteligand.com

Stock Details

Ticker SymbolLGND
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000886163
CUSIP Number53220K504
ISIN NumberUS53220K5048
Employer ID77-0160744
SIC Code2834

Key Executives

NamePosition
Scott M. PleshaChief Executive Officer of Pelthos Therapeutics
Todd C. Davis Ph.D.Chief Executive Officer and Director
Octavio EspinozaChief Financial Officer
Andrew T. Reardon J.D.Chief Legal Officer and Secretary
Paul J. HaddenSenior Vice President of Investments and Business Development
Dr. Keith Marschke Ph.D.Senior Vice President of Biology and Scientific Affairs
Dr. Vincent D. Antle Ph.D.Senior Vice President of Technical Operations and QA - Capitsol
Patrick LucySenior Vice President and CBO Protein Expression Business
Dr. Karen R. Reeves M.D.Senior Vice President of Investments and Head of Clinical Strategy
Richard B. BaxterSenior Vice President of Investment Operation

Latest SEC Filings

DateTypeTitle
Jul 2, 20258-KCurrent Report
Jun 23, 2025144Filing
Jun 10, 2025144Filing
Jun 9, 20258-KCurrent Report
May 15, 2025144Filing
May 14, 2025SCHEDULE 13G/AFiling
May 9, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
Apr 22, 2025ARSFiling
Apr 22, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material